ELMMB logo
Facebook logo Twitter logo
Menu
6.6 Drugs affecting bone metabolism

6.6 Drugs affecting bone metabolism

Management of Patients Receiving Treatment with Bisphosphonates 

Treatment of Osteonecrosis of the Jaw  
RED    Pentoxyfylline tablets (off licence use, consultant use only) 
RED    Vitamin E tablets (off licence use, consultant use only) 
 
Osteoporosis occurs most commonly in postmenopausal women and in those taking long-term oral corticosteroids 
(glucocorticosteroids). Other risk factors for osteoporosis include low body weight, cigarette smoking, excess alcohol intake, lack of 
physical activity, family histroy of osteoporosis, and early menopause. 
 
 Those at risk of osteoporosis should maintain an adequate intake of calcium and 

vitamin D and any deficiency should be corrected by increasing dietary intake or taking supplements.

 
See section 9.5.1.1 for calcium and 9.6.4 for vitamin D replacement, and section 6.4.1 for raloxifene.
 
NICE TA265 -  Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Denosumab is recommended as an option for preventing skeletal-related events (pathological fracture, radiation to bone, spinal
cord compression or surgery to bone) in adults with bone metastases from breast cancer and from solid tumours other than
prostate if:
 
               >     bisphosphonates would otherwise be prescribed and  
               >     the manufacturer provides denosumab with the discount agreed in the patient access scheme.
 
RED                 Denosumab injectionpre-filled syringe 120mg (XGEVA®)
 
 
 
 
 

All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the
 public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service 
  Email: info.elmmb@nhs.net
 Copyright© 2016 East Lancashire Medicines Management Board 
 All rights reserved.  Disclaimer/Terms and conditions